Vasoactive intestinal polypeptide (VIP)-based therapy for blood sugar disease (autoimmune diabetes (TIDM)): Vasoactive intestinal polypeptide (VIP), a peptide hormone known to play a role in heart contractility, vasodilation, and blood pressure,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 24/July/2018,  10.24 pm

A sweet way to lengthen lifespan: Astragalus polysaccharide, isolated from astragalus membraneous,  may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 23/July/2018, 11.58 pm
July 23, 2018
Vaccinate yourself with TB vaccine to lead a pain-free life: TB/BCG vaccine-based activation of the PD-1 pathway for Pain therapy: TB/BCG vaccine, a tuberculosis vaccine,  increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 25/July/2018, 11.20 pm
July 25, 2018
Show all

Introduction: What they say

A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan 20157, Italy; and Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA shows that “PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.” This research paper was published, in the 15 November 2017 issue of the journal “Science Translational Medicine” [One of the best research journals in Science with an I.F of 15 plus], by Prof. Fiorina P and Nasr MB and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Vasoactive intestinal polypeptide (VIP)-based therapy for blood sugar disease (autoimmune diabetes (TIDM)): Vasoactive intestinal polypeptide (VIP), a peptide hormone known to play a role in heart contractility, vasodilation, and blood pressure,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (2) Type 1 Diabetes (T1DM) constitutes about 5-10% (11 to 12 million) of all diabetic cases; (3) the incidence of T1DM is exponentially increasing year after year by 3%; (4) Diabetes is going to be one of the top 10 causes of death by 2030; (5) the life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, while treatment for T1DM costs about $15 billion dollars per annum, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM;(ii) a side-effect-free natural product-based drug that does not harm or deplete adult stem cells; and (iii) a way to cure, not just treat, diabetes.


What is known?

Prof. Fiorina’s research team has recently shown that:(1) programmed death ligand 1 (PD-L1), the immune checkpoint regulator, is expressed poorly in hematopoietic stem and progenitor cells (HSPCs) of Type-1 diabetic (T1D) patients; (2) PD-L1 inhibits activated T-cells and thereby promotes immune tolerance; (3) the expression of PD-L1 is controlled by a network of miRNAs; (4) attenuating the expression of one of the miRNAs that target PD-L1 restores the expression of PD-L1 in HSPCs; (5) increasing the expression of PD-L1 in HSPCs, either genetically or pharmacologically, inhibits autoimmune response and reverses autoimmune diabetes; and (6) PD-L1 is expressed poorly in human HSPCs of T1D patients, suggesting that increasing the expression of PD-L1 in T1D patients may reverse and cure T1D.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, Vasoactive intestinal polypeptide (VIP)-based therapy for autoimmune diabetes. Vasoactive intestinal polypeptide (VIP), by increasing the expression of its target gene, it may increase the expression of PD-L1. Thereby, they may: (1) increase Regulatory T-cells(Tregs) function; (2) decrease immune activation; (3) increase pancreatic-β-cell proliferation and regeneration; (4) increase expression of genes that promote insulin sensitivity and insulin secretion;(4) decrease metabolic stress; and (5) promote glucose homeostasis (Fig.1). Thus,  pharmacological formulations encompassing Vasoactive intestinal polypeptide (VIP) or its activators, either alone or in combination with other drugs, may be used to treat autoimmune diabetes. Taken together, physicians/diabetologists may consider adopting Vasoactive intestinal polypeptide (VIP)-based therapy in the treatment of autoimmune diabetes (T1DM) (Fig.2).

Figure 1. Mechanistic insights into how vasoactive intestinal polypeptide (VIP) prevents the progression of autoimmune diabetes (T1DM). VIP, by increasing the expression of its target genes, it may increase the expression of PD-L1. Thereby, it may prevent immune activation and attenuate the development of T1DM.

Figure 2.  Vasoactive intestinal polypeptide-based therapy may aid in the treatment of autoimmune diabetes through induction of PD-L1


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How Vasoactive intestinal polypeptide (VIP)  increases the expression of PD-L1?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Vasoactive intestinal polypeptide (VIP)-based therapy for blood sugar disease (autoimmune diabetes (TIDM)): Vasoactive intestinal polypeptide (VIP), a peptide hormone known to play a role in heart contractility, vasodilation, and blood pressure,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 24/July/2018,  10.24 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

 

Comments are closed.